Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014)

Zevra Therapeutics (ZVRA) has 1 years of Preferred Stock Liabilities data on file, last reported at $24.2 million in Q4 2014.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $24.2 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $24.2 million (changed N/A YoY) and the FY2014 annual result came in at $24.2 million, up 30.51% from the prior year.
• Preferred Stock Liabilities steadied at $24.2 million in Q4 2014.
• In the past five years, Preferred Stock Liabilities ranged from a high of $24.2 million in Q4 2014 to a low of $24.2 million in Q4 2014.